Compare
Emmaus Life Sciences, Inc. vs Tonix Pharmaceuticals Holding Corp. vs CV Sciences, Inc. vs Arbutus Biopharma Corp
| Latest fiscal year | Emmaus Life Sciences, Inc. EMMA | Tonix Pharmaceuticals Holding Corp. TNXP | CV Sciences, Inc. CVSI | Arbutus Biopharma Corp ABUS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $12.45M | $13.11M | $13.79M | $14.08M |
| Revenue growth (YoY) | -25.2% | +29.8% | -12.2% | +128.2% |
| Gross margin | 93.1% | 49.3% (computed) | 49.0% | n/a |
| Operating margin | 1.9% | -959.1% | -3.4% | -271.0% |
| Net margin | -60.2% | -946.2% | -6.9% | -237.9% |
| Net income | -$7.49M | -$124.02M | -$958.0K | -$33.50M |
| EPS (Diluted) | -$0.12 | -$14.57 | -$0.01 | -$0.17 |
| Operating cash flow | -$11.0K | -$99.84M | -$407.0K | -$39.64M |
| Free cash flow | -$12.0K | -$103.21M | -$516.0K | -$39.64M |
| Cash & equivalents | $2.13M | $207.64M | n/a | $18.01M |
| Total assets | $21.44M | $277.17M | $6.96M | $94.62M |
| Total liabilities | $85.04M | $32.02M | $5.49M | $18.04M |
| Shareholders' equity | -$63.61M | $245.15M | $1.47M | $76.58M |
| Return on year-end equity | n/a | -50.6% | -65.3% | -43.7% |
| Shares outstanding | 70.19M | 12.79M | 184.26M | 192.53M |
Revenue, most recent five fiscal years
| Fiscal year | Emmaus Life Sciences, Inc. | Tonix Pharmaceuticals Holding Corp. | CV Sciences, Inc. | Arbutus Biopharma Corp |
|---|---|---|---|---|
| Latest | $12.45M Ended 2025-12-31 | $13.11M Ended 2025-12-31 | $13.79M Ended 2025-12-31 | $14.08M Ended 2025-12-31 |
| 1 year earlier | $16.65M Ended 2024-12-31 | $10.09M Ended 2024-12-31 | $15.71M Ended 2024-12-31 | $6.17M Ended 2024-12-31 |
| 2 years earlier | $29.60M Ended 2023-12-31 | $7.77M Ended 2023-12-31 | $16.00M Ended 2023-12-31 | $18.14M Ended 2023-12-31 |
| 3 years earlier | $18.39M Ended 2022-12-31 | n/a | $16.20M Ended 2022-12-31 | $39.02M Ended 2022-12-31 |
| 4 years earlier | $20.61M Ended 2021-12-31 | n/a | $20.05M Ended 2021-12-31 | $10.99M Ended 2021-12-31 |